conestat alfa: clinical use

Prescribing considerations

• Initiate under guidance and supervision from a clinician experienced in diagnosing and treating hereditary angioedema.
• Clarify rabbit exposure, rabbit allergy and clinically significant cow's-milk allergy.
• Home administration requires a suitable presentation, competency training, an adverse-reaction plan and periodic review.
• Clinical experience is limited in older adults and absent in hepatic impairment; hepatic dysfunction may prolong elimination.
• Consider sodium content with controlled-sodium diets and assess thromboembolic risk factors.

Contraindications and cautions

• Known or suspected rabbit allergy.
• Hypersensitivity to conestat alfa or any formulation excipient.

Monitoring

• Observe during and after administration for hypersensitivity, which may resemble the underlying attack.
• Assess clinical response and airway involvement promptly.
• Monitor people with thromboembolic risk factors closely.
• Record the product name and batch number.
• Inspect the reconstituted solution for particles or discolouration.

Clinical pharmacology

Conestat alfa is a recombinant analogue with the same amino-acid sequence as endogenous human C1 esterase inhibitor. It inhibits contact- and complement-system proteases and is cleared mainly through receptor-mediated uptake and degradation in the liver.

Formulation and product differences

• The powder-only presentation requires separate water for injections and healthcare-professional administration.
• The powder-and-solvent presentation includes a solvent vial and administration kit and may support trained patient or caregiver administration.
• Both presentations contain a single-use powder vial and produce a clear, colourless intravenous solution after reconstitution.